Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 18/20 | 0.80 |
| ▸ | TACR3 | P29371 | 17/20 | 0.80 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.80 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5908766 | 1.00 | TACR2 (0.80) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL5909035 | 0.91 | TACR2 (0.75) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL5908758 | 0.85 | TACR2 (0.79) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL6853646 | 0.85 | TACR2 (0.77) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL6848770 | 0.84 | TACR2 (0.75) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL27563368 | 0.84 | TACR2 (0.74) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL5908755 | 0.84 | TACR2 (0.70) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL5931004 | 0.83 | TACR2 (0.73) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL5908764 | 0.82 | TACR2 (0.71) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL7169184 | 0.82 | TACR2 (0.71) | TACR2TACR3OPRM1TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097518-A1 | Quinoline derivatives as nk-3 antagonists | GLAXOSMITHKLINE S.P.A. (IT) | 2004-05-20 | — | — | US | disclosed |
| EP-1351953-A1 | QUINOLINE DERIVATIVES AS NK-3 ANTAGONISTS | GlaxoSmithKline S.p.A. (IT) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002044165-A1 | QUINOLINE DERIVATIVES AS NK-3 ANTAGONISTS | GLAXOSMITHKLINE SPA (IT) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097518-A1 | Quinoline derivatives as nk-3 antagonists | KCNK3, KCNQ3, KCNN3 | TACR2 83/4885TACR3 53/4885OPRM1 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.